D Santini1, B Vincenzi1, R Addeo2, C Garufi3, G Masi4, M Scartozzi5, A Mancuso6, A M Frezza1, O Venditti1, M Imperatori1, G Schiavon7, G Bronte8, G Cicero9, F Recine6, E Maiello9, S Cascinu5, A Russo10, A Falcone4, G Tonini1. 1. Department of Medical Oncology, Università Campus Bio-Medico, Rome. 2. Department of Oncology, S Giovanni di Dio Hospital, Frattaminore, Naples. 3. Department of Medical Oncology, Regina Elena Cancer Institute, Rome. 4. Medical Oncology Unit-Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Pisa. 5. Department of Medical Oncology, AO Ospedali Riuniti-Università Politecnica delle Marche, Ancona. 6. Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. 7. Department of Medical Oncology, Erasmus University Medical Center - Daniel den Hoed Cancer Center, Rotterdam, The Netherlands. 8. Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy. 9. Department of Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (Foggia), Italy. 10. Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy. Electronic address: antonio.russo@usa.net.
Abstract
BACKGROUND: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. PATIENTS AND METHODS: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. RESULTS: Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first cycle of the retreatment was 6 months. Overall response rate was 53.8% with 19 partial responses (48.7%) and 2 complete responses (5.1%). Disease stabilization was obtained in 35.9% of patients and progression in four patients (10.2%). Median progression-free survival was 6.6 months. The correlation between skin toxicity during first cetuximab therapy and during cetuximab rechallenge was significant (P = 0.01). CONCLUSION: Rechallenge with the same cetuximab-based therapy may achieve a new important clinical benefit further delaying the progression of disease and improving the therapeutic options.
BACKGROUND: Scientific data provide the evidence that secondary K-RAS mutations do not occur during anti-epidermal growth factor receptor therapy in colorectal cancerpatients. This multicenter phase II prospective study aims to investigate the activity of a retreatment with a cetuximab-based therapy. PATIENTS AND METHODS: We enrolled 39 irinotecan-refractory patients who had a clinical benefit after a line of cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line chemotherapy and finally, after a clear new progression of disease, were retreated with the same cetuximab- plus irinotecan-based therapy. RESULTS: Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first cycle of the retreatment was 6 months. Overall response rate was 53.8% with 19 partial responses (48.7%) and 2 complete responses (5.1%). Disease stabilization was obtained in 35.9% of patients and progression in four patients (10.2%). Median progression-free survival was 6.6 months. The correlation between skin toxicity during first cetuximab therapy and during cetuximab rechallenge was significant (P = 0.01). CONCLUSION: Rechallenge with the same cetuximab-based therapy may achieve a new important clinical benefit further delaying the progression of disease and improving the therapeutic options.
Authors: P García-Alfonso; J García-Foncillas; R Salazar; P Pérez-Segura; R García-Carbonero; E Musulén-Palet; M Cuatrecasas; S Landolfi; S Ramón Y Cajal; S Navarro Journal: Clin Transl Oncol Date: 2014-11-06 Impact factor: 3.405
Authors: M P Morelli; M J Overman; A Dasari; S M A Kazmi; T Mazard; E Vilar; V K Morris; M S Lee; D Herron; C Eng; J Morris; B K Kee; F Janku; F L Deaton; C Garrett; D Maru; F Diehl; P Angenendt; S Kopetz Journal: Ann Oncol Date: 2015-01-26 Impact factor: 32.976